{"id":50439,"date":"2015-10-28T08:36:13","date_gmt":"2015-10-28T12:36:13","guid":{"rendered":"http:\/\/www.hedgeco.net\/news\/?p=50439"},"modified":"2015-10-28T08:41:37","modified_gmt":"2015-10-28T12:41:37","slug":"celgene-patent-on-revlimid-to-be-reviewed-on-bass-challenge","status":"publish","type":"post","link":"https:\/\/www.hedgeco.net\/news\/10\/2015\/celgene-patent-on-revlimid-to-be-reviewed-on-bass-challenge.html","title":{"rendered":"Celgene Patent on Revlimid to Be Reviewed on Bass Challenge"},"content":{"rendered":"<p>(Bloomberg) Hedge-fund manager Kyle Bass has persuaded a federal agency that a Celgene Corp. patent on the blood cancer drug Revlimid may be invalid. The U.S. Patent and Trademark Office on Tuesday said Bass\u2019s Coalition for Affordable Drugs has a \u201creasonable likelihood\u201d of success in his challenge to a patent that expires in 2018. A final decision in the case will come in about a year.\u201cThis patent is another ridiculous example of evergreening by Celgene,\u201d Bass said. \u201cHow is this patentable and how can the patent office possibly facilitate Celgene raising pricing on Revlimid from about $25,000 when first released to now over $180,000? Celgene uses ridiculous patents like this.\u201d<\/p>\n<p><a href=\"http:\/\/www.bloomberg.com\/news\/articles\/2015-10-27\/celgene-patent-on-revlimid-to-be-reviewed-by-u-s-agency\">To read this article:<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>(Bloomberg) Hedge-fund manager Kyle Bass has persuaded a federal agency that a Celgene Corp. patent on the blood cancer drug Revlimid may be invalid. The U.S. Patent and Trademark Office on Tuesday said Bass\u2019s Coalition for Affordable Drugs has a [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-50439","post","type-post","status-publish","format-standard","hentry","category-syndicated"],"_links":{"self":[{"href":"https:\/\/www.hedgeco.net\/news\/wp-json\/wp\/v2\/posts\/50439","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hedgeco.net\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hedgeco.net\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hedgeco.net\/news\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hedgeco.net\/news\/wp-json\/wp\/v2\/comments?post=50439"}],"version-history":[{"count":1,"href":"https:\/\/www.hedgeco.net\/news\/wp-json\/wp\/v2\/posts\/50439\/revisions"}],"predecessor-version":[{"id":50440,"href":"https:\/\/www.hedgeco.net\/news\/wp-json\/wp\/v2\/posts\/50439\/revisions\/50440"}],"wp:attachment":[{"href":"https:\/\/www.hedgeco.net\/news\/wp-json\/wp\/v2\/media?parent=50439"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hedgeco.net\/news\/wp-json\/wp\/v2\/categories?post=50439"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hedgeco.net\/news\/wp-json\/wp\/v2\/tags?post=50439"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}